PSTVCERENOME, INC.
Is Cerenome struggling financially?
Yes, by its own account. Cerenome told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Source filing
- 10-Q 15 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
4months
If the burn speeds up
Empty by Oct 2026
-
6months
If it eases off
Empty by Dec 2026
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$8.6M
÷
Cash burned over the last 12 months
$20.8M
What Cerenome told the SEC
…capital in the future. The Company’s inability to raise additional cash would have a material and adverse impact on its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. As disclosed in more detail in Note 12 Stockholders' Equity , the Company has entered into various financing agreements to raise capital. The Company continues to seek additional…
CERENOME, INC., Form 10-Q, filed 15 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- Cash burn is narrowing It is spending 28% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- GANX Gain Therapeutics $87.5M
- KAPA Kairos Pharma $6.9M
- SINT Sintx Technologies $10.3M
- INO Inovio Pharmaceuticals $122.0M
- GLSI Greenwich Lifesciences $244.7M
- RKTO Rocket One $18.6M